Table: Aska Pharmaceutical -2017/18 group results

ASKA Pharmaceutical Holdings

11/05/2018 07:01

May 11 (Reuters)- 
          Aska Pharmaceutical Co Ltd 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2018    Mar 31, 2017   Mar 31, 2019     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           48.94           48.53          49.00        24.00    
               (+0.9 pct)      (+12.3 pct)    (+0.1 pct)    (-4.2 pct) 
  Operating        2.82            1.79           1.00       200 mln   
               (+57.4 pct)     (+39.7 pct)    (-64.6 pct)  (-89.3 pct) 
  Recurring        3.07            2.00           1.20       300 mln   
               (+53.5 pct)     (+31.6 pct)    (-61.0 pct)  (-84.9 pct) 
  Net                                             1.00       200 mln   
                                              (-58.1 pct)  (-87.8 pct) 
  Net              2.39            2.94                                
               (-18.9 pct)    (+319.8 pct)                             
  EPS           84.80 yen      105.39 yen      35.47 yen     7.09 yen  
  Ann Div       14.00 yen       14.00 yen      14.00 yen               
  -Q2 Div       7.00 yen        7.00 yen       7.00 yen                
  -Q4 Div       7.00 yen        7.00 yen       7.00 yen                
  
  NOTE - Aska Pharmaceutical Co Ltd.
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4514.T